The U.S. Food and Drug Administration (FDA) recently convened a panel to discuss the use and safety of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs).


The U.S. Food and Drug Administration (FDA) recently convened a panel to discuss the use and safety of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs).